• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, July 14, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Predicting relapses in patients with autoimmune vascular disease

Bioengineer by Bioengineer
May 23, 2018
in Health
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Patients with an autoimmune disorder called antineutrophil cytoplasmic antibody-associated vasculitis produce antibodies that damage blood vessels in the body. In some cases, patients' antibodies target a protein called myeloperoxidase. New research published in Arthritis & Rheumatology indicates that for patients in remission, reappearance of antibodies against myeloperoxidase is a sign that patients will experience a relapse of their disease.

The findings suggest that patients should undergo routine monitoring of antibodies against myeloperoxidase.

"Our results could be helpful in daily clinical practice related to antineutrophil cytoplasmic antibody-associated vasculitis," said co-author Dr. Ken-Ei Sada, of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, in Japan.

###

Media Contact

Penny Smith
[email protected]

http://newsroom.wiley.com/

http://dx.doi.org/10.1002/art.40538

Share12Tweet8Share2ShareShareShare2

Related Posts

GSA Report Spotlights Brain Health Breakthroughs and Primary Care Challenges

July 14, 2026

People With Disabilities Face Much Higher Rates of Alcohol Use Disorder

July 14, 2026

First Space Diagnostic X-rays Signal a New Era for Astronaut Health

July 14, 2026

Treatment delays in colorectal cancer linked to higher metastasis risk thresholds

July 14, 2026
Please login to join discussion

POPULAR NEWS

  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15
  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • Experimental Therapy Simultaneously Destroys Prostate Tumor Cells and Reactivates Antitumor Immunity

    46 shares
    Share 18 Tweet 12
  • 高齢者の骨粗鬆症治療の持続性比較

    51 shares
    Share 20 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Study finds most pregnant people fail recommended seatbelt placement, despite safety need

Sustained virtual smoking cessation doubles quit rates for cancer patients

Global study links ultrafine air particles to nearly two million premature deaths annually

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.